Corteva (NYSE:CTVA) Price Target Raised to $93.00

Corteva (NYSE:CTVA) had its price target increased by investment analysts at CICC Research from $80.00 to $93.00 in a report released on Wednesday,MarketScreener reports. The brokerage currently has an “outperform” rating on the stock. CICC Research’s target price would indicate a potential upside of 12.45% from the stock’s previous close.

Several other analysts have also recently issued reports on CTVA. Citigroup upped their price objective on shares of Corteva from $83.00 to $85.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Argus upped their target price on Corteva from $80.00 to $91.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. UBS Group raised their target price on Corteva from $88.00 to $90.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded Corteva from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, May 7th. Finally, Zacks Research cut shares of Corteva from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 20th. Thirteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.14.

Corteva Stock Up 0.1%

Shares of NYSE CTVA opened at $82.70 on Wednesday. The firm has a market cap of $55.31 billion, a price-to-earnings ratio of 48.71, a price-to-earnings-growth ratio of 2.68 and a beta of 0.59. The company’s 50-day simple moving average is $80.88 and its 200-day simple moving average is $73.03. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. Corteva has a 52-week low of $60.53 and a 52-week high of $85.63.

Corteva (NYSE:CTVA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The company had revenue of $4.91 billion for the quarter, compared to analysts’ expectations of $4.64 billion. During the same period in the previous year, the firm posted $1.13 EPS. Corteva’s revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Equities analysts predict that Corteva will post 3.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Corteva news, insider Brian Titus sold 8,311 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares of the company’s stock, valued at $619,289.50. This trade represents a 50.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.15% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corteva

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Activest Wealth Management grew its position in shares of Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company’s stock worth $25,000 after acquiring an additional 200 shares during the last quarter. JPL Wealth Management LLC purchased a new position in Corteva during the 3rd quarter worth $25,000. Garton & Associates Financial Advisors LLC acquired a new position in Corteva in the fourth quarter valued at $27,000. Bank of Jackson Hole Trust purchased a new stake in shares of Corteva in the fourth quarter valued at about $28,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Corteva in the third quarter valued at about $29,000. 81.54% of the stock is currently owned by institutional investors and hedge funds.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.